ATE533766T1 - Chinolinderivate als ep4-antagonisten - Google Patents

Chinolinderivate als ep4-antagonisten

Info

Publication number: ATE533766T1
Authority: AT; Austria
Prior art keywords: derivatives; group; quinoline derivatives; antagonists; formula
Prior art date: 2005-05-19

Application number

AT06741503T

Other languages

English (en)

Inventor

Michel Belley

Jason Burch

John Colucci

Julie Farand

Mario Girard

Yongxin Han

Original Assignee

Merck Canada Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-19

Filing date

2006-05-15

Publication date

2011-12-15

2006-05-15 Application filed by Merck Canada Inc filed Critical Merck Canada Inc

2011-12-15 Application granted granted Critical

2011-12-15 Publication of ATE533766T1 publication Critical patent/ATE533766T1/de

Links

229940027991 antiseptic and disinfectant quinoline derivative Drugs 0.000 title abstract 2
SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
239000005557 antagonist Substances 0.000 title 1
229910052757 nitrogen Inorganic materials 0.000 abstract 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
208000002193 Pain Diseases 0.000 abstract 2
125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
208000000094 Chronic Pain Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000001154 acute effect Effects 0.000 abstract 1
208000005298 acute pain Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
229910052799 carbon Inorganic materials 0.000 abstract 1
125000004432 carbon atom Chemical group C* 0.000 abstract 1
XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
201000008482 osteoarthritis Diseases 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
125000002943 quinolinyl group Chemical class N1=C(C=CC2=CC=CC=C12)* 0.000 abstract 1
239000002464 receptor antagonist Substances 0.000 abstract 1
229940044551 receptor antagonist Drugs 0.000 abstract 1
206010039073 rheumatoid arthritis Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Addiction (AREA)
Rheumatology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Psychiatry (AREA)
Orthopedic Medicine & Surgery (AREA)
Ophthalmology & Optometry (AREA)
Obesity (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Psychology (AREA)
Urology & Nephrology (AREA)
Virology (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
AIDS & HIV (AREA)

AT06741503T 2005-05-19 2006-05-15 Chinolinderivate als ep4-antagonisten ATE533766T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US68258905P	2005-05-19	2005-05-19
PCT/CA2006/000789 WO2006122403A1 (en)	2005-05-19	2006-05-15	Quinoline derivatives as ep4 antagonists

Publications (1)

Publication Number	Publication Date
ATE533766T1 true ATE533766T1 (de)	2011-12-15

Family

ID=37430885

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT06741503T ATE533766T1 (de)	2005-05-19	2006-05-15	Chinolinderivate als ep4-antagonisten

Country Status (7)

Country	Link
US (1)	US8013159B2 (de)
EP (1)	EP1885722B1 (de)
JP (1)	JP5289046B2 (de)
AT (1)	ATE533766T1 (de)
AU (1)	AU2006246930C1 (de)
CA (1)	CA2608214C (de)
WO (1)	WO2006122403A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AR057023A1 (es) *	2005-05-16	2007-11-14	Gilead Sciences Inc	Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
UY30121A1 (es)	2006-02-03	2007-08-31	Glaxo Group Ltd	Nuevos compuestos
AU2007331471C1 (en) *	2006-12-15	2013-07-25	Glaxo Group Limited	Benzamide derivatives as EP4 receptor agonists
CA2679175C (en) *	2007-02-26	2015-01-13	Merck Frosst Canada Ltd.	Indole and indoline cyclopropyl amide derivatives as ep4 receptor antagonists
CN101636385B (zh) *	2007-03-26	2012-09-05	默克弗罗斯特加拿大有限公司	作为ep4受体拮抗剂的萘和喹啉磺酰脲衍生物
GB0721611D0 (en)	2007-11-02	2007-12-12	Glaxo Group Ltd	Novel compounds
WO2010034110A1 (en)	2008-09-25	2010-04-01	Merck Frosst Canada Ltd.	Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
EP2392323A4 (de)	2009-01-30	2012-09-26	Univ Kyoto	Progressionshemmer für prostatakrebs und verfahren zur progressionshemmung
EP2965756B1 (de)	2009-04-22	2018-10-10	AskAt Inc.	Selektive ep4-rezeptorantagonistensubstanz zur krebsbehandlung
EP2555773A1 (de)	2010-04-08	2013-02-13	Boehringer Ingelheim International GmbH	Arzneimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
EP2555774B1 (de) *	2010-04-08	2015-10-21	Boehringer Ingelheim International GmbH	Arnzeimittelkombinationen enthaltend pde4-inhibitoren und ep4-rezeptor-antagonisten
WO2014143591A1 (en)	2013-03-12	2014-09-18	Allergan, Inc.	Inhibition of neovascularization by simultaneous inhibition of prostanoid ip and ep4 receptors
CR20180323A (es)	2015-11-20	2018-08-06	Idorsia Pharmaceuticals Ltd	Derivados de indol n-sustituídos como moduladores de los receptores de pge2
US10342785B2 (en)	2016-11-04	2019-07-09	Askat Inc.	Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
US11839613B2 (en)	2017-05-18	2023-12-12	Idorsia Pharmaceuticals Ltd	Pyrimidine derivatives as PGE2 receptor modulators
TWI768043B (zh)	2017-05-18	2022-06-21	瑞士商愛杜西亞製藥有限公司	N-取代吲哚衍生物
PE20191814A1 (es)	2017-05-18	2019-12-27	Idorsia Pharmaceuticals Ltd	Derivados de pirimidina como moduladores del receptor de pge2
TW201900179A (zh)	2017-05-18	2019-01-01	瑞士商愛杜西亞製藥有限公司	作為pge2受體調節劑之苯并呋喃及苯并噻吩衍生物
KR102612140B1 (ko)	2017-05-18	2023-12-08	이도르시아 파마슈티컬스 리미티드	피리미딘 유도체
US20230390303A1 (en)	2020-11-13	2023-12-07	Ono Pharmaceutical Co., Ltd.	Cancer treatment by combination of ep4 antagonist and immune checkpoint inhibitor

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU8807882A (en) *	1981-09-21	1983-03-31	Mobil Oil Corp.	Catalyst composition with zeolite support
GB9417532D0 (en) *	1994-08-31	1994-10-19	Zeneca Ltd	Aromatic compounds
GB9420557D0 (en) *	1994-10-12	1994-11-30	Zeneca Ltd	Aromatic compounds
US5834468A (en)	1995-07-07	1998-11-10	Zeneca Limited	Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists
WO2000021542A1 (en)	1998-10-15	2000-04-20	Merck & Co., Inc.	Methods for stimulating bone formation
GB0031302D0 (en) *	2000-12-21	2001-01-31	Glaxo Group Ltd	Napthalene derivatives
GB0031295D0 (en) *	2000-12-21	2001-01-31	Glaxo Group Ltd	Naphthalene derivatives
GB0103269D0 (en) *	2001-02-09	2001-03-28	Glaxo Group Ltd	Napthalene derivatives
CA2369967A1 (en)	2001-02-12	2002-08-12	Joseph Anthony Cornicelli	Methods of treating nuclear factor-kappa b mediated diseases and disorders
CA2466757A1 (en) *	2001-12-03	2003-06-12	Merck & Co., Inc.	Method for treating ocular hypertension
AU2002350315B2 (en) *	2001-12-14	2008-05-22	Merck Frosst Canada Ltd	Quinolinones as prostaglandin receptor ligands
AU2003262947A1 (en)	2002-08-30	2004-03-19	Pharmacia And Upjohn Company	Method of preventing or treating atherosclerosis or restenosis
WO2004035577A2 (en)	2002-10-16	2004-04-29	Gilead Sciences, Inc.	Pre-organized tricyclic integrase inhibitor compounds
AU2003275840A1 (en) *	2002-10-25	2004-05-13	Merck Frosst Canada Ltd	2-pyrrolidones as EP4 receptor agonists
AU2004234087A1 (en)	2003-04-28	2004-11-11	Tibotec Pharmaceuticals Ltd.	HIV integrase inhibitors
EP1736467A4 (de)	2004-04-06	2009-07-01	Dainippon Sumitomo Pharma Co	Neues sulfonsäureamidderivat
WO2005117904A2 (en)	2004-04-14	2005-12-15	Gilead Sciences, Inc.	Phosphonate analogs of hiv integrase inhibitor compounds
CA2576850C (en)	2004-08-30	2013-06-25	Janssen Pharmaceutica N.V.	Tricyclic lactam derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors

2006
- 2006-05-15 WO PCT/CA2006/000789 patent/WO2006122403A1/en not_active Ceased
- 2006-05-15 AU AU2006246930A patent/AU2006246930C1/en not_active Ceased
- 2006-05-15 EP EP06741503A patent/EP1885722B1/de active Active
- 2006-05-15 JP JP2008511515A patent/JP5289046B2/ja not_active Expired - Fee Related
- 2006-05-15 US US11/920,275 patent/US8013159B2/en active Active
- 2006-05-15 AT AT06741503T patent/ATE533766T1/de active
- 2006-05-15 CA CA2608214A patent/CA2608214C/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US8013159B2 (en)	2011-09-06
CA2608214C (en)	2013-08-20
US20090099226A1 (en)	2009-04-16
JP5289046B2 (ja)	2013-09-11
AU2006246930C1 (en)	2012-01-19
AU2006246930A1 (en)	2006-11-23
JP2008540584A (ja)	2008-11-20
EP1885722A4 (de)	2010-02-24
CA2608214A1 (en)	2006-11-23
EP1885722A1 (de)	2008-02-13
AU2006246930B2 (en)	2011-08-18
EP1885722B1 (de)	2011-11-16
WO2006122403A1 (en)	2006-11-23

Publication	Publication Date	Title
ATE533766T1 (de)	2011-12-15	Chinolinderivate als ep4-antagonisten
DK1853602T3 (da)	2010-09-20	Kemiske forbindelser
CY1108275T1 (el)	2014-02-12	Χημικες ενωσεις
EA200900658A1 (ru)	2009-12-30	Производные индазолилэфиров или -амидов для лечения расстройств, опосредованных глюкокортиодными рецепторами
EA200801738A1 (ru)	2008-12-30	Пиперидиноилпирролидиновые агонисты меланокортинового рецептора 4 типа
EA201100524A1 (ru)	2011-10-31	Азаиндазолы в качестве антагонистов рецептора ccr1
EA201070988A1 (ru)	2011-12-30	Противовирусные терапевтические средства
EA201170531A1 (ru)	2011-10-31	Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака
GEP20146125B (en)	2014-07-25	Aminopyrimidines as syk inhibitors
EA201001683A1 (ru)	2011-06-30	Производные фенил- или пиридинилзамещенных индазолов
ATE429427T1 (de)	2009-05-15	Pyrimidinderivate als orexin-rezeptorantagonisten
EA200970156A1 (ru)	2009-08-28	Пиридизиноновые производные
EA200900983A1 (ru)	2010-02-26	Соединения и композиции в качестве ингибиторов киназы
EA200970085A1 (ru)	2009-06-30	Замещённые n-фенилметил-5-оксопролин-2-амиды в качестве антагонистов р2х7-рецептора и способы их применения
EA201000113A1 (ru)	2010-08-30	Пиразольные соединения
EA200700168A1 (ru)	2007-06-29	Производные замещенной циклической мочевины, их получение и их фармацевтическое применение в качестве ингибиторов киназы
BRPI0510177B8 (pt)	2021-05-25	composto, composição farmacêutica e uso do mesmo
EA200601350A1 (ru)	2007-04-27	Азотсодержащие гетероциклические производные и их фармацевтические применения
EA200701808A1 (ru)	2008-02-28	Производные тетрагидроиндолона и тетрагидроиндазолона
BRPI0410349A (pt)	2006-05-30	inibidores de benzamida do receptor p2x7
SE0303180D0 (sv)	2003-11-26	Novel compounds
SE0302232D0 (sv)	2003-08-18	Novel Compounds
MY149512A (en)	2013-09-13	Pyrazolylaminopyridine derivatives useful as kinase inhibitors
EA200700601A1 (ru)	2008-02-28	Производные фениламинопиримидина как ингибиторы bcr-abl
EA200970065A1 (ru)	2009-06-30	Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38